Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Anil Rustgi, the new director of the Herbert Irving Comprehensive Cancer Center, talks about new ideas in cancer research, the best patient care, and the importance of physician-scientists.
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.
A new study suggests that a type of brain tumor in patients with neurofibromatosis type 1 could be treated with immunotherapy, which has so far proved ineffective in treating most brain cancers.
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
A new study found that women with cervical cancer who had a radical hysterectomy with minimally invasive surgery had a significantly higher risk of death than those who had open surgery.